The use of frailty models in genetic studies: application to the relationship between end-stage renal failure and mutation type in Alport syndrome. European Community Alport Syndrome Concerted Action Group (ECASCA)
- PMID: 11051113
The use of frailty models in genetic studies: application to the relationship between end-stage renal failure and mutation type in Alport syndrome. European Community Alport Syndrome Concerted Action Group (ECASCA)
Abstract
Background: Alport syndrome (AS) is a severe hereditary disease usually transmitted as an X dominant trait and involving a mutation of the COL4A5 gene. It leads to end-stage renal failure (ESRF), but this progression is heterogeneous. Mutations of the COL4A5 gene have been characterised in numerous families using molecular biology. Our objective was to evaluate the interfamilial heterogeneity of the disease and to study relationships between mutation types and progression to ESRF in the European Community Alport Syndrome Concerted Action group (ECASCA) registry database.
Methods: We used the frailty model framework. Frailty models have been developed to analyse censored data with non-independent observations. Random effects are introduced in a Cox proportional regression model to take into account the intracluster correlations. In this study, ESRF is considered a censored event and the intrafamilial correlations are taken into account in the frailty models.
Results: These approaches allow us to demonstrate the existence of an interfamilial heterogeneity; the role of the mutation type explains the interfamilial variability. In particular, the results suggest that some mutation types are associated with a higher risk of ESRF for males.
Conclusions: This study shows the importance of characterising the mutation at the molecular level in genetic studies, to understand the relationship between genotype and phenotype. The frailty models constitute an attractive approach in this context, when the phenotype is characterised by a censored end-point.
Similar articles
-
[Methodology for analyzing censored correlated data: application of marginal and frailty approaches in human genetics. The European Community Alport Syndrome Concerted Action Group (ECASCA)].Rev Epidemiol Sante Publique. 1999 Dec;47(6):545-54. Rev Epidemiol Sante Publique. 1999. PMID: 10673588 French.
-
Alport syndrome. Molecular genetic aspects.Dan Med Bull. 2009 Aug;56(3):105-52. Dan Med Bull. 2009. PMID: 19728970
-
X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a "European Community Alport Syndrome Concerted Action" study.J Am Soc Nephrol. 2003 Oct;14(10):2603-10. doi: 10.1097/01.asn.0000090034.71205.74. J Am Soc Nephrol. 2003. PMID: 14514738
-
[Clinical and genetic features of the Alport 'syndromes'].G Ital Nefrol. 2005 Sep-Oct;22(5):466-76. G Ital Nefrol. 2005. PMID: 16267804 Review. Italian.
-
[From Alport syndrome to benign familial hematuria: clinical and genetic aspect].Nephrol Ther. 2005 May;1(2):90-100. doi: 10.1016/j.nephro.2005.03.005. Epub 2005 Jun 1. Nephrol Ther. 2005. PMID: 16895672 Review. French.
Cited by
-
Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients.World J Surg. 2010 Feb;34(2):249-55. doi: 10.1007/s00268-009-0290-1. World J Surg. 2010. PMID: 19949948
Publication types
MeSH terms
LinkOut - more resources
Medical
Research Materials